Bio-Rad Laboratories Inc. (BIO) Options Positioning, Max Pain & Unusual Sweeps

BIO scores 66 out of 100, earning a C+ and the verdict "Roarable Hold — Upper Neutral / Watch for Breakout." The five pillars are: Fundamental Cash Engine at 7/20 (ROIC 0.5%; FCF yield 3.64%), Whale 13F Flow at 17/20 (institutional accumulation and options positioning), Insider Conviction at 14/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 12/20 (Beta 1.04; sector sensitivity), and Forensic Balance Sheet at 16/20 (Altman Z 3.59; Piotroski F 7/9; Debt/Equity 0.16).

The profile is uneven. The weakest pillar is the cash engine, where a 0.5% ROIC and a 7/20 score signal that the business is not currently converting capital into high returns, even though the FCF yield of 3.64% provides some cash-generation support. The strongest pillars are institutional flow and the balance sheet, which together suggest that large holders are positioned constructively and that leverage is not a near-term constraint. For a prospective investor, the upside case rests on the balance-sheet strength and institutional interest persisting while operating returns improve; the valuation tradeoff is that the stock trades at a P/E of 13.5 (TTM) against an EV/EBITDA of 60.4, a combination that makes the earnings base look modest relative to the enterprise value.

Bio-Rad Laboratories Inc. (BIO) is a NYSE-listed issuer in the Health Care sector, operating in the Biotechnology: Laboratory Analytical Instruments industry. The source data identifies the company's market capitalization as $10.3B. Revenue is reported in the SEC financials at $2.58B for FY 2025.

Operating income fell from $337.8M (FY 2023) to $269.0M (FY 2024) to $47.2M (FY 2025), while reported net income swung from losses to $759.9M in FY 2025. The market data reports a gross margin of 51.9%, an operating margin of 1.8%, and a net margin of 29.4%, with ROIC at 0.5%. The forensic balance sheet pillar cites an Altman Z-Score of 3.59 and a Piotroski F-Score of 7/9, with Debt/Equity at 0.16. Free cash flow was positive in each reported period, rising to $374.6M in FY 2025, and the source data shows debt roughly stable near $1.2B over FY 2024 and FY 2025.

• 🐂 Primary Bull Case: Strong balance-sheet forensics (Altman Z 3.59, Piotroski F 7/9, Debt/Equity 0.16) and high institutional flow support the rating despite weak returns on capital. With Fundamental Cash Engine at 7/20 (ROIC 0.5%, FCF yield 3.64%) and Institutional Whale Flow at 13/20, sustained execution supports upside toward the top of the $236.73 – $396.23 52-week range.
• 🐻 Primary Bear Case: ROIC of 0.5% and an operating margin of 1.8% indicate the core business earns very little on its capital, with EV/EBITDA at 60.4 far above the 13.5 P/E. Investors must weigh 13.5x trailing P/E and 60.4x EV/EBITDA against 1.8% operating margins and a 1.04 macro beta if sector demand softens.

The only sector context provided is Health Care / Biotechnology: Laboratory Analytical Instruments, and the beta of 1.04 per the market data. An investor should not infer specific supplier or customer ripple effects from the source material.

• Key Question #1: What do the Q3 results scheduled for Nov. 4 show regarding operating income trajectory from $47.2M in FY 2025?
• Key Question #2: Why is the EPS field "N/A" for all three reported periods while TTM EPS is listed at 28.42?
• Key Question #3: How sensitive is BIO's 51.9% gross margin and 12.6x forward P/E multiple to Health Care demand cycles and macro interest-rate shifts (Beta 1.04)?